A股異動 | 龍蟠科技(603906.SH)跌約5% 建投嘉馳擬減持不超2%股份
格隆匯12月30日丨龍蟠科技(603906.SH)現報30.08元,跌4.96%,暫成交3.79億元,最新總市值103億元。龍蟠科技昨日晚間發公吿稱,公司持股5.23%的股東建投嘉馳(上海)投資有限公司,擬通過集中競價方式減持不超過688.74萬股,即不超過公司總股本的2%。值得一提的是,龍蟠科技上週五(25日)晚間公佈,擬收購貝特瑞並表範圍內的磷酸鐵鋰相關資產和業務,該股於本週一(28日)、週二連續兩日漲停,今日盤中創出歷史新高價32.5元后迅速回落轉跌,該股今年迄今仍累漲近1.9倍。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.